A Case of Azacitidine-Induced Toxic Erythema of Chemotherapy
Main Article Content
Keywords
toxic erythema of chemotherapy, azacitidine, TEC
Abstract
Toxic Erythema of Chemotherapy (TEC) is a well-described spectrum of overlapping toxic reactions to chemotherapy, clinically characterized by painful erythematous, violaceous, and/or edematous plaques of the hands, feet, and intertriginous regions that may have a dusky appearance and develop bullae with subsequent erosions. TEC is most often associated with use of cytarabine, anthracyclines, 5‐fluorouracil, capecitabine, taxanes, and methotrexate. however, no prior occurrence of TEC following azacitidine therapy has been reported. Here we present a rare case of azacitidine-induced TEC in an 83-year-old female patient.
References
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, phase III study. Lancet Oncol. 2009;10(3):223-32.
Silverman LR. DNA methyltransferase inhibitors in myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004;17(4):585-94.
Almeida AM, Pierdomenico F. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone. Leuk Res. 2012;36(9):e211-3.
Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy:a useful clinical term. J Am Acad Dermatol. 2008;59(3):524-9.
NG ES, Aw DC, Tan KB, et al. Neutrophilic eccrine hidradenitis associated with decitabine. Leuk Res. 2010;34(5):e130-2.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.